From VXCL 10k-One interesting factor is the symbiotic relationship that is developing larger pharmaceuticals and Bio-techs. This is evident in VXCL's strategy.
following are excerpts from most recent 10k:
Vaxcel's business strategy is to sublicense its technologies on a
vaccine-by-vaccine basis to companies engaged in vaccine development. Such
sublicense agreements may be either exclusive, co-exclusive, or non-exclusive
in the field depending upon the situation. The sublicensees will combine their
vaccine with Vaxcel's technology and then be responsible for product
development, regulatory approval, and commercialization of the final product at
their expense. In return, Vaxcel will receive licensing fees, milestone
payments, and royalty on sales. At present, Vaxcel has entered into an option
agreement for Optivax with Medeva PLC ("Medeva")(MDV), a license agreement for
Optivax with Corixa Corporation ("Corixa")(CRXA), and a license agreement for PLG
microspheres with ALK A/S ("ALK")(European).... ...
In addition to the above mentioned corporate collaborations, Vaxcel
has several research and materials transfer agreements with leading vaccine
manufacturers and biotechnology companies whereby Vaxcel has provided its
adjuvant/delivery system technology for evaluation with their antigens. Under
other arrangements, some companies have provided Vaxcel with their antigens to
be tested in conjunction with Vaxcel's adjuvant/delivery system technology.
Assuming successful results from such evaluations, Vaxcel will aggressively
pursue sublicensing agreements or other arrangements with certain of these
research partners. |
